← Product Code [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX) · K214049
# Leaseir MHR Xcell (K214049)
_Leaseir Technologies, Slu · GEX · Jun 2, 2022 · General, Plastic Surgery · SESE_
**Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K214049
## Device Facts
- **Applicant:** Leaseir Technologies, Slu
- **Product Code:** [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX.md)
- **Decision Date:** Jun 2, 2022
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 878.4810
- **Device Class:** Class 2
- **Review Panel:** General, Plastic Surgery
- **Attributes:** Therapeutic
## Intended Use
Indications for use for Leaseir MHR Xcell diode laser hair removal system with 810mm applicator includes: · Hair Removal with Static and Dynamic modes intended for permanent reduction in hair regrowth, defined as a long term, stable reduction in the number of hairs re-growing when measured at 6, 9, and 12 months after the completion of a treatment regime. · Treatment of Pseudofolliculitis barbae (PFB) · Use on all skin types (Fitzpatrick I-VI)
## Device Story
Leaseir MHR Xcell is a diode laser surgical instrument for hair removal and PFB treatment. System comprises a main console and two interchangeable applicators (810nm wavelength). Operates via selective photothermolysis; AlGaAs laser diode array generates light pulses; sapphire (Al2O3) tip contacts skin. Two modes: static (1-4 Hz) and dynamic (10 Hz). Physician-operated in clinical settings. Trigger on handpiece activates continuous pulse pattern. Output energy heats hair follicles and oxyhemoglobin to destroy targets while cooling tip protects epidermis. Cooling system uses phase-change refrigerated coolant pumped to applicator tip (-4°C to +4°C). Clinical benefit is long-term, stable hair regrowth reduction.
## Clinical Evidence
Bench testing only. Compliance with IEC 60601-1 (electrical safety), IEC 60601-1-2 (EMC), IEC 60601-2-22 (laser safety), IEC 60825-1 (laser classification), ISO 14971 (risk management), ISO 10993-1 (biocompatibility), and IEC 62366-1 (usability). No clinical data presented.
## Technological Characteristics
AlGaAs laser diode stack; 810nm wavelength; sapphire (Al2O3) contact tip; phase-change liquid cooling system (-4°C to +4°C); LCD touchscreen interface; finger switch activation. Dimensions: 1100x450x570mm; Weight: 48kg. Power: 100-130V, 50/60 Hz. Class IV laser. Software compliant with IEC 62304.
## Regulatory Identification
(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
## Predicate Devices
- ELYSION-PRO ([K193367](/device/K193367.md))
## Submission Summary (Full Text)
> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. Underneath the square are the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
June 2, 2022
Leaseir Technologies S.L.U. % Vardhini Kirthivas Vice President - Quality & Regulatory Affairs Freyr Global Regulatory Solutions and Services Level 4 Building No. H-08, Phoenix SEZ Phase 2 Gachibowli, Hyderabad, Telangana 500081 India
Re: K214049
Trade/Device Name: Leaseir MHR Xcell Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: April 28, 2022 Received: May 3, 2022
Dear Vardhini Kirthivas:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Purva Pandya, D.Eng. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K214049
Device Name Leaseir MHR Xcell
Indications for Use (Describe)
Indications for use for Leaseir MHR Xcell diode laser hair removal system with 810mm applicator includes: · Hair Removal with Static and Dynamic modes intended for permanent reduction in hair regrowth, defined as a long term, stable reduction in the number of hairs re-growing when measured at 6, 9, and 12 months after the completion of a treatment regime.
· Treatment of Pseudofolliculitis barbae (PFB)
· Use on all skin types (Fitzpatrick I-VI)
| Type of Use (Select one or both, as applicable) | |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## 510(k) Summary (K214049)
| 1. Submitter Information: | |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Application Correspondent: | Vardhini Kirthivas
Freyr Global Regulatory Solutions and Service
Level 4, Building No. H-08, Phoenix SEZ,
Phase 2, Gachibowli, Hyderabad,
Telangana, India, 500081 |
| Phone: | +91 - 9940445965 |
| E-mail: | usagent@freyrsolutions.com |
| Legal Manufacturer: | Leaseir Technologies S.L.U.,
C/ Jimena Fernández de la Vega, 140 1ºH,
33203 Gijón,
Asturias, Spain |
| Phone: | +34 666 57 75 07 |
| Contact Person: | Pablo Boto |
| E-mail: | pboto@leaseir.com |
| Date Prepared: | 01-June-2022 |
#### 2. Device Identification:
| Device Trade Name: | Leaseir MHR Xcell |
|----------------------|-----------------------------------|
| Common Name: | Powered Laser Surgical Instrument |
| Classification Name: | Powered Laser Surgical Instrument |
### Table 1 Device Identification
| Regulation No. | Product Code | Device Class |
|-----------------|--------------|--------------|
| 21 CFR 878.4810 | GEX | Class II |
### 3. Predicate Device
ELYSION-PRO by High Technology Products SLU with the K-Number K193367
#### 4. Device Description
The Leaseir MHR Xcell is a surgical laser instrument for use in general and plastic surgery and dermatology, intended for hair removal and treatment of pseudo folliculitis barbae on all skin types (Fitzpatrick I-VI).
The process implies the generation of intense light pulses at specific wavelengths. The specific nature of the energies and pulse durations cause the desired effect (in the hair follicles and oxyhemoglobin in the blood) heating them sufficiently and destroying them without unnecessary damage to surrounding tissue. This is achieved by controlled emission of laser radiation to the target tissue.
{4}------------------------------------------------
The system consists of a main console and two interchangeable applicators that delivers pulsed light in the range of 800-820nm with a peak in the 810nm in different spot sizes. Two of the applicators emitting radiation at 810 nm wavelength for two areas 13.5×15 mm² and 14.5×25.5 mm². Two different operation modes are available: static mode and dynamic mode, which are differentiated basically by the frequency range defined for each mode (1-4 Hz for static and 10 Hz for dynamic).
The principle of operation consists in the photons travel along the axis and reflected again back into the crystal, continuing the chain reaction, while photons travelling in different directions leave the crystal. In one of the two mirrors, a tiny hole allows a small amount of light to leak out and the resulting beam is focused with lenses and is emitted from the laser. The total energy emitted by the Leaseir MHR Xcell is produced by an array of diodes.
The laser emission is activated by the hand piece trigger, deliver a continuous pulse pattern while the button is pressed.
### 5. Intended Use and Indications for Use
Indications for use for Leaseir MHR Xcell diode laser hair removal system with 810nm applicator includes:
- Hair Removal with Static and Dynamic modes intended for permanent ● reduction in hair regrowth, defined as a long term, stable reduction in the number of hairs re-growing when measured at 6, 9, and 12 months after the completion of a treatment regime.
- Treatment of Pseudofolliculitis barbae (PFB)
- Use on all skin types (Fitzpatrick I-VI) ●
### Comparison of Technological Characteristics with Predicate Device 6.
The following table is used to compare the technological characteristics of the subject device, Leaseir MHR Xcell with those of the predicate device, Elysion-Pro.
{5}------------------------------------------------
| Parameters for
Substantial
Equivalence | Subject Device
Leaseir MHR Xcell | Predicate Device
Elysion-Pro | Remarks |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 510(k) Number | N/A | K193367 | |
| Manufacturer | Leaseir Technologies | High Technology
Products SLU | N/A |
| Product code | GEX | GEX | SE |
| Regulation
number | 878.4810 | 878.4810 | SE |
| Panel | General
&
Plastic
Surgery | General
&
Plastic
Surgery | SE |
| Class | II | II | SE |
| of
Principle
Operation | AlGaAs laser diode
stack | AlGaAs laser diode
array | SE |
| Laser contact | Pure sapphire, Al2O3 | Pure sapphire, Al2O3 | SE |
| Laser wavelength | Dual 810b: 810nm
Quad 810b:810nm | 755nm, 810 nm | SE |
| Laser
classification | Class IV | Class IV | SE |
| Spot
sizes | Dual 810b: 13.5x15 | 10x10 | The spot size of the proposed device is different from the spot sizes of the predicate |
| (mmxmm) | Quad 810b:14.5x25.5 | 18x10 | device. The Leaseir Dual 810b and Quad 810b spots are larger than predicate device (This
statement is taking in account that there are two available spot sizes for both subject and
predicate device, the Leaseir Dual 810b 13,5x15 is larger than Elysion 10x10, as well as
Quad 810b 14,5x25,5 is larger than Elysion 18x10). Fluence is lowered with increasing
spot size to heat dermal targets effectively and to avoid side effects in the epidermis and |
| Parameters for
Substantial
Equivalence | Subject Device
Leaseir MHR Xcell | Predicate Device
Elysion-Pro | Remarks |
| 510(k) Number | N/A | K193367 | |
| Fluence | Dual 810b: 60J/cm2
Quad 810b: 48J/cm2 | 70J/cm2 | the upper dermis. The spot size and fluence have been adjusted accordingly. Hence, the
safety and effectiveness of the device would not get affected. Also, the non-clinical tests
conducted for the device, renders the device to be safe and effective.
Fluence is a key factor in laser therapy. The fluency of the proposed device is slightly
different from the fluency of the Elysion-pro. However, the maximum fluence limited by
the software remains exactly same. The spot sizes and fluence are adjusted to heat dermal targets effectively. The non-clinical testing conducted for the device, demonstrates that the subject device is safe and effective for the proposed indications for use. |
| Maximum
Fluence limited
by the software
(as per the
treatment table) | 40J/cm2 | 40J/cm2 | SE |
| Frequency | Static: Up to 4 Hz
Dynamic: 10 Hz | Static: Up to 3 Hz
Dynamic:5-15 Hz | The frequency for the proposed device is slightly different from predicate device.
However, the frequency range for the proposed device can be covered in the range of
predicate device. Therefore, this difference will not affect substantial equivalence
between proposed device and equivalent device. The justification in combination with the
non-clinical testing demonstrates the safety and equivalence of the subject device |
| Pulse Duration | 1-400ms | 3 - 400ms | SE |
| Optical Peak
Power (W) | 4000 W | 2000 W | Power and spot size are individual parameters that, when combined, provide power
density. This combination defines how much energy and heat are delivered to the desired
target. A general rule is that when the spot size is increased by half, the fluence should be
decreased by half to create an effect at the same treatment depth because of the scattering
of the incident beam. The laser diode power was calculated to achieve the same fluence
when compared to the predicate device. maintaining the pulse durations |
| Parameters for
Substantial
Equivalence | Subject Device | Predicate Device | Remarks |
| | Leaseir MHR Xcell | Elysion-Pro | |
| 510(k) Number | N/A | K193367 | |
| Treatment mode | Static and Dynamic | Static and Dynamic | SE |
| Tissue cooling | Contact
continuous,
liquid cooled | Contact continuous,
thermo-electrical | The difference between the subject device and the predicate is the method to cool down
the tip. The predicate uses a TEC (Thermo Electric Cooling) that consists of a
semiconductor device that maintains temperature difference between two parallel planes
when an electrical current is applied. In the case of the Leaseir MHR Xcell, a tank of
coolant is refrigerated by a phase-change cooler. This results in amount of coolant at a
temperature between -6 and -2 Celsius degrees available to cool down different parts of
the system when necessary. The coolant is pumped to the laser head and applied part tip
by pipes through the umbilical cord.
Cooling is an important part of the process, particularly for patient comfort and customer
satisfaction. The slight difference between the cooling temperature of subject device and
predicate device does not affect the safety and effectiveness of the device |
| Cooling
Temperature | -4°C to +4°C | 5°C | |
| User Interface | LCD touchscreen | LCD touchscreen | SE |
| Pulsing Control | Finger switch | Finger switch | SE |
| Removable
Applicators | Set of 2 removable
applicators,
Dual
810b and Quad 810b | Set of 3 removable
applicators | The subject and predicate devices differ in the number of applicators provided. The
different applicators are intended to give the user the chance to change the laser aperture
spot in order to fit the areas of the body to be treated. Both devices provide spot sizes that
are suitable for all the body areas to be treated and are capable to maintain the necessary
energy density on the spot, hence this difference does not raise any difference in safety
and effectiveness of the device. |
| Configuration | Main unit and hand
pieces | Main unit, handpiece,
and foot control
(optional) | SE |
| Parameters for
Substantial
Equivalence | Subject Device
Leaseir MHR Xcell | Predicate Device
Elysion-Pro | Remarks |
| 510(k) Number | N/A | K193367 | |
| Power Supply | Single phase
100-130V
50/60 Hz | Single-phase
100-240V
50/60 Hz | The predicate device covers a wider power supply range (100-240V 50/60Hz) that covers
all the different ac mains configurations. The Leaseir MHR Xcell is intended to work in
specific supply ranges, providing two different device models, the 110b and the 220b.
The US market will be covered by the 110b model, with a power supply range of 100-
130V 50/60 Hz that works on the US voltages (120V +/-6%). This model is the subject
of the present submissions. The 220b will not be marketed on the US, hence is not
considered in this submission. |
| Dimension
(HxWxD) | 1100x450x570mm | 650x500x450mm | The dimension and weight for the proposed device is different from predicate device.
However, the dimension and weight are physical specifications, and this difference does
not raise any issues in safety and effectiveness of the subject device. |
| Weight | 48Kg | 38Kg | |
## Table 2 Summary of the comparison of Technological Characteristics
{6}------------------------------------------------
{7}------------------------------------------------
{8}------------------------------------------------
{9}------------------------------------------------
Indication for use statements of both the proposed and the predicate device are compared in the following table,
### Table 3 Comparison of Intended Use
| Parameter | Subject Device | Predicate Device | Remarks |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Leaseir MHR Xcell | Elysion-Pro | |
| Indications for use | Indications for use for Leaseir MHR Xcell
diode laser hair removal system with 810nm
applicator includes:
• Hair Removal with Static and Dynamic
modes intended for permanent reduction
in hair regrowth, defined as a long term,
stable reduction in the number of hairs
re-growing when measured at 6, 9, and
12 months after the completion of a
treatment regime.
• Treatment of Pseudofolliculitis barbae
(PFB)
• Use on all skin types (Fitzpatrick I-VI) | Indications for use for ELYSION diode laser hair removal
system with 755nm and 810nm applicators include:
• Hair Removal with Static and Dynamic modes intended for
permanent reduction in hair regrowth, defined as a long term,
stable reduction in the number of hairs re-growing when
measured at 6, 9, and 12 months after the completion of a
treatment regime.
• Treatment of Pseudofolliculitis barbae (PFB)
• Use on all skin types (Fitzpatrick I-VI). | Similar. Since Leaseir MHR Xcell
used two applicators with 810nm
wavelength. Also Leaseir MHR
Xcell has two modes (Static and
Dynamic) which is equivalent to
Predicate device Elysion-Pro. |
{10}------------------------------------------------
### 7. Harmonized Standards Complied
Table 4 Standards Complied by Subject and Predicate Device
| S. No. | Standard | Subject Device | Predicate Device |
|------------------------------------|----------------|----------------|------------------|
| Electrical Safety/Radiation Safety | | | |
| 1 | IEC 60601-1 | Pass | Pass |
| 2 | IEC 60601-1-2 | Pass | Pass |
| 3 | IEC 60601-2-22 | Pass | Pass |
| 4 | IEC 60825-1 | Pass | Pass |
| Software in a Medical Device | | | |
| 5 | IEC 62304 | Pass | Pass |
| Risk Analysis | | | |
| 6 | ISO 14971 | Pass | Pass |
| Biocompatibility | | | |
| 7 | ISO 10993-1 | Pass | Pass |
### Comparison Summary 8.
### 8.1 Intended Use
The intended use of the subject and predicate device is the same.
### 8.2 Similar characteristics
From the above comparative tables, the proposed medical device has the same intended use of hair removal and treatment of pseudo folliculitis barbae on all skin types (Fitzpatrick I-VI), as the predicate device and has similar technological characteristics.
Mechanism of action of all the devices (predicate and the new device) is photothermolysis, i.e., destruction of a follicle due to an increase of the temperature induced by a high-powered beam of light which is selectively absorbed by the melanin.
The subject and predicate device have the same configuration of Main Unit, Handpiece, LCD User Interface. Pulsing Control, and the laser energy is delivered through the applicator by means of a Finger Switch. Principle of operation of all the devices is using same energy source laser diode and the material of the laser diode is AlGaAs, which is same for the subject device and the predicate device. The laser contacting part of the applicator/handpiece is Sapphire for all the devices and the material of the sapphire is Al2O3 which is same for the subject and predicate device. The treatments modes (Static and Dynamic modes) between the subject and predicate device are found to be the same. Leaseir MHR Xcell has the pulse duration equivalent to the predicate device.
{11}------------------------------------------------
### 8.3 Differences
As explained in the Substantial Equivalence Table the differences do not substantially alter the intended use as both are non-invasive aesthetic laser for use in surgical applications in the medical specialties.
### Non-Clinical Testing 9.
Testing conducted to evaluate the functional performance and safety of the Leaseir MHR Xcell equipment. The test results demonstrated that the proposed device complies with the following standards:
- 1. ANSI AAMI ES60601-1:2005/(R)2012 with amendments Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD).
- 2. IEC 60601-1-2 Edition 4.0 2014-02 Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests.
- IEC 62304 Edition 1.1 2015-06 CONSOLIDATED VERSION Medical device 3. software - Software life cycle processes.
- 4. IEC 60601-2-22 Edition 3.1 2012-10 Medical electrical equipment Part 2-22: Requirements for basic safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment.
- 5. IEC 60825-1 Edition 2.0 2007-03 Safety of laser products Part 1: Equipment classification, and requirements [Including: Technical Corrigendum 1 (2008), Interpretation Sheet 1 (2007), Interpretation Sheet 2 (2007).
- 6. ISO 14971 Third Edition 2019-12 Medical devices Application of risk management to medical devices.
- 7. IEC 62366-1 Edition 1.1 2020-06 CONSOLIDATED VERSION Medical devices -Part 1: Application of usability engineering to medical devices.
- 8. ISO 10993-1 Fifth edition 2018-08 Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process.
## 10. Substantial Equivalence Conclusion
Based on the above technological specification comparison and justifications of the differences provided, the subject device is determined to be substantially equivalent to the predicate device.
---
**Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K214049](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K214049)
**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).
**Cite:** Innolitics at https://innolitics.com